BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35325271)

  • 1. A multicentre cohort study assessing the utility of routine blood tests as adjuncts to identify complete responders in rectal cancer following neoadjuvant chemoradiotherapy.
    Eastern Rectal Cancer Response Collaborative, Ireland
    Int J Colorectal Dis; 2022 Apr; 37(4):957-965. PubMed ID: 35325271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
    Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term outcomes of real world 'watch and wait' data for rectal cancer after neoadjuvant chemoradiotherapy.
    Simpson G; Hopley P; Wilson J; Day N; Haworth A; Montazeri A; Smith D; Titu L; Anderson J; Agbamu D; Walsh C
    Colorectal Dis; 2020 Nov; 22(11):1568-1576. PubMed ID: 32686268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 5. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234).
    Wang L; Zhang XY; Zhao YM; Li SJ; Li ZW; Sun YS; Wang WH; Wu AW;
    Ann Surg; 2023 Apr; 277(4):647-654. PubMed ID: 35766394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application of magnetic resonance in "non-operative treatment" strategy for rectal cancer].
    Wang Y; Chen G
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jun; 20(6):630-634. PubMed ID: 28643307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term prognostic analysis on complete/near-complete clinical remission for mid-low rectal cancer after neoadjuvant chemoradiotherapy].
    Wang L; Li S; Zhang X; Sun T; Du C; Chen N; Peng Y; Yao Y; Zhan T; Zhao J; Cai Y; Li Y; Wang W; Li Z; Sun Y; Ji J; Wu A
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1240-1248. PubMed ID: 30506534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 9. [Diagnosis and treatment strategy for clinical complete responders after chemoradiotherapy for rectal cancer: is watch-and-wait policy safe?].
    Yao HW; Liu YH
    Zhonghua Wai Ke Za Zhi; 2017 Jul; 55(7):496-499. PubMed ID: 28655076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
    Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
    PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Total neoadjuvant therapy followed by watch and wait approach or organ preservation for MRI stratified low-risk rectal cancer: early result from a prospective, single arm trial].
    Wang L; Zhao YM; Sun TT; Xu YL; Li SJ; Zhang XY; Cai Y; Li YH; Li ZW; Chen PJ; Peng YF; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):258-265. PubMed ID: 32192305
    [No Abstract]   [Full Text] [Related]  

  • 12. Systemic Immune-inflammation Index (SII) Predicts Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.
    Eraslan E; Adas YG; Yildiz F; Gulesen AI; Karacin C; Arslan UY
    J Coll Physicians Surg Pak; 2021 Apr; 31(4):399-404. PubMed ID: 33866724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application value of colonoscopic assessment in "watch and wait" strategy for mid-lower rectal cancer after neoadjuvant chemoradiotherapy].
    Li SJ; Wang L; Zhang XY; Li YH; Li ZW; Wu Q; Sun YS; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jul; 22(7):648-655. PubMed ID: 31302963
    [No Abstract]   [Full Text] [Related]  

  • 14. Initial magnetic resonance imaging tumour regression grade (mrTRG) as response evaluation after neoadjuvant treatment predicts sustained complete response in patients with rectal cancer.
    Suzuki C; Halperin SK; Nilsson PJ; Martling A; Holm T
    Eur J Surg Oncol; 2022 Jul; 48(7):1643-1649. PubMed ID: 35272899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemoradiotherapy might provide survival benefit in patients with stage IIIb/IIIc locally advanced rectal cancer: A retrospective single-institution study with propensity score-matched comparative analysis.
    Sun XY; Cai SH; Xu L; Luo D; Qiu HZ; Wu B; Lin GL; Lu JY; Zhang GN; Xiao Y
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):142-149. PubMed ID: 32031326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular calcification and response to neoadjuvant therapy in locally advanced rectal cancer: an exploratory study.
    Knight KA; Drami I; McMillan DC; Horgan PG; Park JH; Jenkins JT; Roxburgh CSD
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3409-3420. PubMed ID: 33710416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictive value of combination of MRI tumor regression grade and apparent diffusion coefficient for pathological complete remission after neoadjuvant treatment of locally advanced rectal cancer].
    Xu N; Huang FC; Li WL; Luan X; Jiang YM; He B
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Apr; 24(4):359-365. PubMed ID: 33878826
    [No Abstract]   [Full Text] [Related]  

  • 18. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 19. Delaying surgery after neoadjuvant chemoradiotherapy in rectal cancer has no influence in surgical approach or short-term clinical outcomes.
    Figueiredo N; Panteleimonitis S; Popeskou S; Cunha JF; Qureshi T; Beets GL; Heald RJ; Parvaiz A
    Eur J Surg Oncol; 2018 Apr; 44(4):484-489. PubMed ID: 29398323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Outcome of watch and wait strategy or organ preservation for rectal cancer following neoadjuvant chemoradiotherapy: report of 35 cases from a single cancer center].
    Wu A; Wang L; Du C; Peng Y; Yao Y; Zhao J; Zhan T; Cai Y; Li Y; Sun Y; Ji J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):417-424. PubMed ID: 28440523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.